Capital Impact Advisors LLC reduced its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 27.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,768 shares of the biotechnology company’s stock after selling 20,981 shares during the period. Capital Impact Advisors LLC’s holdings in Ironwood Pharmaceuticals were worth $1,034,000 as of its most recent filing with the SEC.
A number of other large investors have also recently made changes to their positions in the stock. V Wealth Management LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth about $313,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth about $652,000. Point72 Asset Management L.P. raised its stake in shares of Ironwood Pharmaceuticals by 458.4% in the first quarter. Point72 Asset Management L.P. now owns 1,628,018 shares of the biotechnology company’s stock worth $27,774,000 after buying an additional 1,336,486 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth about $194,000. Finally, Gotham Asset Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 176.8% in the first quarter. Gotham Asset Management LLC now owns 363,051 shares of the biotechnology company’s stock worth $6,194,000 after buying an additional 231,888 shares in the last quarter. 97.36% of the stock is currently owned by institutional investors and hedge funds.
Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) traded down 0.59% on Friday, hitting $16.90. The company’s stock had a trading volume of 560,626 shares. The stock’s market cap is $2.51 billion. The firm has a 50 day moving average of $18.52 and a 200-day moving average of $17.04. Ironwood Pharmaceuticals, Inc. has a 12 month low of $12.48 and a 12 month high of $19.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Monday, May 8th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.14. Ironwood Pharmaceuticals had a negative net margin of 46.49% and a negative return on equity of 195.06%. The company had revenue of $52.16 million during the quarter, compared to the consensus estimate of $69.39 million. During the same quarter in the prior year, the business earned ($0.08) EPS. The firm’s revenue for the quarter was down 21.0% compared to the same quarter last year. On average, analysts expect that Ironwood Pharmaceuticals, Inc. will post ($0.91) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Capital Impact Advisors LLC Sells 20,981 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/07/21/capital-impact-advisors-llc-sells-20981-shares-of-ironwood-pharmaceuticals-inc-nasdaqirwd.html.
A number of brokerages recently issued reports on IRWD. J P Morgan Chase & Co reissued a “neutral” rating on shares of Ironwood Pharmaceuticals in a research report on Friday. Zacks Investment Research raised Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday. BidaskClub raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Mizuho lifted their target price on Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, July 4th. Finally, Wedbush reissued a “neutral” rating and issued a $13.00 target price on shares of Ironwood Pharmaceuticals in a research report on Friday, June 16th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Ironwood Pharmaceuticals presently has an average rating of “Hold” and an average target price of $18.20.
In other news, insider Thomas A. Mccourt sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $18.20, for a total value of $546,000.00. Following the transaction, the insider now owns 30,000 shares in the company, valued at $546,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Halley E. Gilbert sold 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $19.75, for a total value of $691,250.00. Following the completion of the transaction, the insider now owns 35,000 shares in the company, valued at approximately $691,250. The disclosure for this sale can be found here. 7.63% of the stock is owned by company insiders.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
